Daudén Esteban, Ortiz-Salvador José María, Notario Jaime, Puig Lluís, Santos-Juanes Jorge, Herrera-Acosta Enrique, Gómez-Labrador Lara, Ruiz-Villaverde Ricardo
Dermatology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), 28006 Madrid, Spain.
Dermatology Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain.
J Clin Med. 2025 Jan 13;14(2):478. doi: 10.3390/jcm14020478.
: Secukinumab was shown to be effective in treating moderate-to-severe plaque psoriasis in adults and pediatric patients ≥6 years. : A literature review was conducted to identify studies published in the preceding 5 years assessing the effectiveness and/or survival (safety in the second instance) associated with secukinumab treatment for moderate-to-severe plaque psoriasis with/without psoriatic arthritis (PsA) in real-world clinical practice in Spain. : 11 references were included, corresponding to seven studies (six retrospective and one prospective) (n = 1050). Baseline characteristics were mean age 46.5-53.0 years; 28.7-55.0% women; 30.0-53.1% patients with PsA; 27.9-47.4% naïve to biologic treatments; mean Psoriasis Area and Severity Index (PASI) score 12.5 (standard deviation [SD]: 6.9)-18.1 (SD: 10.3). PASI 90 response rates were 54-65% at Week 24 and 46-63% at Week 52; 43-47% of patients showed PASI ≤ 1 at Week 12 and 47-56% at Week 52. Treatment persistence at Week 52 was 72-89%, being 74.5% in the larger cohort series (n = 384) at 2 years. Adverse-event-related treatment discontinuation was rare. : Secukinumab demonstrated long-term safety and efficacy in treating adult patients with moderate-to-severe plaque psoriasis in actual clinical practice, with survival rates of up to two years and consistent efficacy in Spain.
司库奇尤单抗已被证明对治疗成人及≥6岁的儿童中重度斑块状银屑病有效。进行了一项文献综述，以确定过去5年发表的研究，这些研究评估了在西班牙实际临床实践中，司库奇尤单抗治疗伴有或不伴有银屑病关节炎（PsA）的中重度斑块状银屑病的有效性和/或生存率（其次是安全性）。纳入了11篇参考文献，对应7项研究（6项回顾性研究和1项前瞻性研究）（n = 1050）。基线特征为平均年龄46.5 - 53.0岁；女性占28.7 - 55.0%；PsA患者占30.0 - 53.1%；初次接受生物治疗的患者占27.9 - 47.4%；银屑病面积和严重程度指数（PASI）平均得分12.5（标准差[SD]：6.9） - 18.1（SD：10.3）。在第24周时，达到PASI 90缓解率的患者为54 - 65%，在第52周时为46 - 63%；43 - 47%的患者在第12周时PASI≤1，在第52周时为47 - 56%。在第52周时的治疗持续率为72 - 89%，在2年时更大的队列系列（n = 384）中为74.5%。与不良事件相关的治疗中断很少见。在西班牙的实际临床实践中，司库奇尤单抗在治疗成人中重度斑块状银屑病方面显示出长期安全性和有效性，生存率可达两年且疗效持续一致。
